替沙来塞仑在成人复发或难治性滤泡性淋巴瘤中的应用:2期ELARA试验
ELARA是一项2期跨国试验,评估替沙来塞仑治疗既往≥2线或自体干细胞移植后复发的成人复发/难治性滤泡性淋巴瘤。截至2021年3月29日,98例入组中97例接受输注,中位随访16.59个月。疗效集94例完全缓解率69.1%(95%CI 58.8-78.3),总缓解率86.2%(95%CI 77.5-92.4)。安全性集97例中细胞因子释放综合征48.5%(≥3级0%),神经系统事件37.1%(≥3级3%),ICANS 4.1%(≥3级1%),无治疗相关死亡。
要点
- 疗效集完全缓解率69.1%,总缓解率86.2%。
- 细胞因子释放综合征48.5%,≥3级0%;神经系统事件37.1%,≥3级3%。
- 无治疗相关死亡,在高度预处理患者中安全有效。
核心结论
- 替沙来塞仑在高度预处理的复发/难治性滤泡性淋巴瘤(包括高危患者)中安全有效。
研究设计与样本
- ELARA为2期跨国试验(NCT03568461),入组成人复发/难治性滤泡性淋巴瘤,既往≥2线治疗或自体干细胞移植后复发。
- 共入组98例,97例接受替沙来塞仑输注;疗效集94例,安全性集97例。
- 主要终点为完全缓解率,次要终点包括总缓解率、缓解持续时间、无进展生存、总生存、药代动力学和安全性。
- 截至2021年3月29日,中位随访16.59个月(四分位距13.8-20.21)。
主要发现
- 疗效集(n=94)完全缓解率69.1%(95%CI 58.8-78.3),总缓解率86.2%(95%CI 77.5-92.4)。
- 安全性集(n=97)输注后8周内细胞因子释放综合征发生率48.5%(≥3级0%)。
- 神经系统事件发生率37.1%(≥3级3%),免疫效应细胞相关神经毒性综合征(ICANS)发生率4.1%(≥3级1%)。
- 无治疗相关死亡。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tisagenlecleucel is an autologous anti-CD19 chimeric antigen receptor-T cell therapy with clinically meaningful outcomes demonstrated in patients with relapsed/refractory (r/r) B-cell lymphoma. In a previous pilot study of tisagenlecleucel in r/r follicular lymphoma (FL), 71% of patients achieved a complete response (CR). Here we report the primary, prespecified interim analysis of the ELARA phase 2 multinational trial of tisagenlecleucel in adults with r/r FL after two or more treatment lines or who relapsed after autologous stem cell transplant (no. NCT03568461). The primary endpoint was CR rate (CRR). Secondary endpoints included overall response rate (ORR), duration of response, progression-free survival, overall survival, pharmacokinetics and safety. As of 29 March 2021, 97/98 enrolled patients received tisagenlecleucel (median follow-up, 16.59 months; interquartile range, 13.8-20.21). The primary endpoint was met. In the efficacy set (n = 94), CRR was 69.1% (95% confidence interval, 58.8-78.3) and ORR 86.2% (95% confidence interval, 77.5-92.4). Within 8 weeks of infusion, rates of cytokine release syndrome were 48.5% (grade ≥3, 0%), neurological events 37.1% (grade ≥3, 3%) and immune effector cell-associated neurotoxicity syndrome (ICANS) 4.1% (grade ≥3, 1%) in the safety set (n = 97), with no treatment-related deaths. Tisagenlecleucel is safe and effective in extensively pretreated r/r FL, including in high-risk patients.
引用
- Fowler NH, Dickinson M, Dreyling M, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2021. PMID: 34921238. doi:10.1038/s41591-021-01622-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。